Nadav Ahituv

Nadav Ahituv, PhD, is a Professor in the Department of Bioengineering at the University of California, San Francisco (UCSF) School of Pharmacy. His research focuses on identifying gene regulatory elements and linking nucleotide variations to phenotypes such as morphological differences, drug responses, and human diseases. He pioneered techniques like massively parallel reporter assays (MPRAs) and cis-regulation therapy (CRT), and developed adipose modulation transplantation (AMT) for cancer therapy.

Ahituv earned his PhD with distinction from Tel Aviv University in 2002. His work integrates genomic and computational approaches to study gene regulation in health and disease. Key research areas include functional characterization of enhancers, evolutionary genomics, and translational therapies targeting regulatory elements.

His laboratory has received significant funding from NIH grants, including projects on obesity genetics, hernia susceptibility, and psychiatric disorder-associated regulatory elements. Recent publications highlight advancements in MPRAs, CRISPR-based screens, and the role of nullomers in disease.

Awards include the 2024 ASHG Scientific Achievement Award and the 2014 ASCPT Leon I. Goldberg Young Investigator Award. Collaborations span institutions like UCSF, Stanford, and international research groups, reflecting his interdisciplinary approach to biomedical research.